iX Biopharma (42C) Fundamentals 2026 — Revenue Analysis | SniperIQ
iX Biopharma (42C) is a SG-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of S$431M, trading at S$0.40 on the SES. This SniperIQ fundamentals page covers iX Biopharma's valuation, profitability (net margin -85.2%), revenue (S$8M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is iX Biopharma's market cap?
iX Biopharma (42C) has a market capitalization of approximately S$431M, trading at S$0.40 on the SES. Market cap moves with the live share price.
What is iX Biopharma's P/E ratio?
iX Biopharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 95.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is iX Biopharma?
iX Biopharma runs a net profit margin of -85.2%, a gross margin of 32.2%, and an operating margin of -80.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does iX Biopharma generate?
iX Biopharma reported revenue of S$8M for fiscal year 2024, with net income of -S
Does iX Biopharma pay a dividend?
iX Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is iX Biopharma financially healthy?
iX Biopharma carries a debt-to-equity ratio of 1.63x and a current ratio of 1.05x, with a market beta of 1.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is iX Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For iX Biopharma (42C) the key facts are: market cap S$431M, revenue S$8M, 52-week range 0.018-0.46. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track iX Biopharma's full fundamentals live
Get iX Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.